Q32 Bio
Stock Forecast, Prediction & Price Target
Q32 Bio (QTTB) stock Price Target by analysts
$72
Potential upside: 3856.04%
Q32 Bio price prediction
What is Q32 Bio stock analysts` prediction?
Q32 Bio stock forecast: Based on 2 Wall Street analysts` predicted price targets for Q32 Bio in the last 3 months, the avarage price target is $72, with a high forecast of $NaN. The average price target represents a 3856.04% change from the last price of $1.82.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
Q32 Bio stock Price Target by analysts
Full breakdown of analysts given Q32 Bio price targets
| Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
|---|---|---|---|---|---|---|
Etzer Darout BMO Capital | 0% 0/1 | 10 months ago | $64 3416.48% upside | $23.69 | StreetInsider | Previous targets (0) |
Jay Olson Oppenheimer | 0% 0/2 | 12 months ago | $80 4295.60% upside | $48.47 | StreetInsider | Previous targets (1) |
Derek Archila Wells Fargo | 0% 0/1 | about 1 year ago | $95 5119.78% upside | $50.61 | StreetInsider | Previous targets (0) |
Thomas Smith Leerink Partners | 0% 0/1 | over 1 year ago | $54 2867.03% upside | $30.2 | TheFly | Previous targets (0) |
Jay Olson Oppenheimer | 0% 0/2 | over 1 year ago | $50 2647.25% upside | $21.48 | StreetInsider | Previous targets (1) |
Allison Bratzel Piper Sandler | 0% 0/1 | over 1 year ago | $45 2372.52% upside | $18 | StreetInsider | Previous targets (0) |
Christopher Raymond Raymond James | 0% 0/1 | over 1 year ago | $45 2372.52% upside | $18 | TheFly | Previous targets (0) |
Q32 Bio Financial Estimates
Q32 Bio Revenue Estimates
Q32 Bio EBITDA Estimates
Q32 Bio Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $33.97M N/A | $6.65M -80.42% | $1.15M -82.61% | Avg: $2M Low: $2M High: $2M avg. 73.01% | Avg: $2M Low: $2M High: $2M avg. 0% | Avg: $2M Low: $2M High: $2M avg. 0% | Avg: $57.71M Low: $57.71M High: $57.71M avg. 2785.76% |
Net Income
% change YoY
| $-37.56M N/A | $-42.80M -13.96% | $-112.96M -163.87% | Avg: $-14.74M Low: $-17.06M High: $-10.53M avg. 86.94% | Avg: $-20.62M Low: $-20.62M High: $-20.62M avg. -39.86% | Avg: $-27.45M Low: $-27.45M High: $-27.45M avg. -33.09% | Avg: $-27.58M Low: $-27.58M High: $-27.58M avg. -0.46% |
EBITDA
% change YoY
| $-36.64M N/A | $-36.45M 0.52% | $-86.50M -137.29% | Avg: $-2M Low: $-2M High: $-2M avg. 97.68% | Avg: $-2M Low: $-2M High: $-2M avg. 0% | Avg: $-2M Low: $-2M High: $-2M avg. 0% | Avg: $-57.71M Low: $-57.71M High: $-57.71M avg. -2785.76% |
EPS
% change YoY
| -$12.23 N/A | -$13.42 -9.73% | -$35.16 -161.99% | Avg: -$4.59 Low: -$5.31 High: -$3.28 avg. 86.94% | Avg: -$6.42 Low: -$6.42 High: -$6.42 avg. -39.86% | Avg: -$8.55 Low: -$8.55 High: -$8.55 avg. -33.09% | Avg: -$8.59 Low: -$8.59 High: -$8.59 avg. -0.46% |
Operating Expenses
% change YoY
| $36.69M N/A | $45.87M 25.02% | $92.68M 102.02% | Avg: $18.61M Low: $18.61M High: $18.61M avg. -79.90% | Avg: $18.61M Low: $18.61M High: $18.61M avg. 0% | Avg: $18.61M Low: $18.61M High: $18.61M avg. 0% | Avg: $537.32M Low: $537.32M High: $537.32M avg. 2785.76% |
FAQ
What is Q32 Bio stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 3.37% in 2025-2028.
We have gathered data from 3 analysts. Their low estimate is -17.06M, average is -14.74M and high is -10.53M.
What is Q32 Bio stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 714.69% in 2025-2028.
We have gathered data from 3 analysts. Their low revenue estimate is $2M, average is $2M and high is $2M.
What is Q32 Bio stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 3.37% in 2025-2028.
We have gathered data from 3 analysts. Their low earnings per share estimate is -$5.31, average is -$4.59 and high is $-3.28.
What is the best performing analyst?
In the last twelve months 2 analysts have been covering Q32 Bio stock. The most successful analyst is Etzer Darout.